You have 9 free searches left this month | for more free features.

M0

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Stratification for pT4bN0M0 Colorectal Cancer Following

Completed
  • Colorectal Cancer
  • multivisceral resection
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Oct 30, 2023

Lung Adenocarcinoma, Lymph Node Metastasis Trial in Shanghai (Selective Lymph Node Dissection)

Recruiting
  • Lung Adenocarcinoma
  • Lymph Node Metastasis
  • Selective Lymph Node Dissection
  • Shanghai, Please Select, China
    Chaoqiang Deng
Sep 4, 2023

Oral Squamous Cell Carcinoma, Neck Dissection Trial (Elective neck dissection, Therapeutic neck dissection)

Not yet recruiting
  • Oral Squamous Cell Carcinoma
  • Neck Dissection
  • Elective neck dissection
  • Therapeutic neck dissection
  • (no location specified)
Apr 10, 2023

Early Supraglottic Squamous Cell Carcinoma With Advance

Recruiting
  • Supraglottic Squamous Cell Carcinoma
  • Early Stage (T1-T2, N0-N1,M0)
  • TORS
  • Yvoir, Namur, Belgium
    CHU UCL Namur
Nov 3, 2022

Esophageal Cancer Trial in Moscow (Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy.,

Recruiting
  • Esophageal Cancer
  • Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy.
  • Patients undergoing neoadjuvant chemotherapy plus Ivory-Lewis or McKeown esophagectomy
  • Moscow, Russian Federation
    N.N. Blokhin National Medical Research Center of Oncology
Oct 2, 2022

Oral Cancer, PD-1 Trial in Guangzhou (PD-1 with chemo, upright surgery)

Recruiting
  • Oral Cancer
  • PD-1
  • PD-1 with chemotherapy
  • upright surgery
  • Guangzhou, Guangdong, China
    Sun yat-sen memorial hospital
Nov 12, 2023

Esophageal Squamous Cell Carcinoma Trial in Tokyo (Chemoradiotherapy)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Chemoradiotherapy
  • Tokyo, Japan
    National Cancer Center Hospital
Apr 5, 2022

Colorectal Cancer, Adjuvant Chemo Trial in Guangzhou (wait and watch, adjuvant chemo)

Recruiting
  • Colorectal Cancer
  • Adjuvant Chemotherapy
  • wait and watch
  • adjuvant chemotherapy
  • Guangzhou, Guangdong, China
    Sixth Affiliated Hospital of Sun Yat-sen University
Jan 25, 2022

Esophageal Cancer Trial (SDD)

Not yet recruiting
  • Esophageal Cancer
  • (no location specified)
May 9, 2023

Urinary Bladder Cancer Trial in Guangzhou (Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin)

Recruiting
  • Urinary Bladder Cancer
  • Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin
  • Guangzhou, Guangdong, China
    Zhujiang Hospital
Jan 6, 2023

Nasopharyngeal Carcinoma Trial in Guangzhou (Induction chemo plus Concurrent chemo, Concurrent chemo, IMRT)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Induction chemotherapy plus Concurrent chemotherapy
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Nov 17, 2022

Rectal Cancer Trial in Sabadell (drug, radiation, procedure)

Completed
  • Rectal Cancer
  • Capecitabine (Xeloda)
  • +3 more
  • Sabadell, Barcelona, Spain
    Corporació Parc Taulí
Nov 15, 2021

Rheumatoid Arthritis Trial in Montpellier (Abatacept (M3-M12), TNF Inhibitor (M3-M12), TNF Inhibitor (M0-M3))

Not yet recruiting
  • Rheumatoid Arthritis
  • Abatacept (M3-M12)
  • +2 more
  • Montpellier, France
    Centre Hospitalier Universitaire de Montpellier
Jun 16, 2022

Urinary Bladder Tumors Trial in Xi'an (drug, procedure, radiation)

Not yet recruiting
  • Urinary Bladder Neoplasms
  • Tislelizumab Injection
  • +2 more
  • Xi'an, Shaanxi, China
    First Affiliated Hospital of Xian Jiaotong University
Dec 26, 2022

Rectal Cancer, Adenocarcinoma Trial in Seongnam (Tailored surgery, Total mesorectal excision (TME))

Recruiting
  • Rectal Cancer, Adenocarcinoma
  • Tailored surgery
  • Total mesorectal excision (TME)
  • Seongnam, Korea, Republic of
    Seoul National University Bundang Hospital
Jan 5, 2022

Rectal Adenocarcinoma Trial in Baltimore (FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin}, Low dose fractionated

Terminated
  • Rectal Adenocarcinoma
  • FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin}
  • Low dose fractionated radiation therapy (LDFRT)
  • Baltimore, Maryland
    Ummc Msgcc
Oct 6, 2021

NSCLC Trial in Shanghai (VATS, Thoracotomy)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • VATS
  • Thoracotomy
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 20, 2022

Mouth Tumors, Carcinoma, Squamous Cell Trial in Shanghai (drug, procedure, radiation)

Recruiting
  • Mouth Neoplasms
  • Carcinoma, Squamous Cell
  • TPF induction chemotherapy
  • +2 more
  • Shanghai, Shanghai, China
    Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong
Oct 5, 2022

Urothelial Carcinoma Bladder, PD-1 Inhibitor Trial in Shanghai (Tislelizumab, Gemcitabine, Cisplatin)

Recruiting
  • Urothelial Carcinoma Bladder
  • PD-1 Inhibitor
  • Shanghai, Shanghai, China
    Renji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Aug 15, 2022

End-stage Kidney Disease Trial in Brampton, Toronto (SUPPORT-DIALYSIS with Access to Output Report and Information Hub,

Not yet recruiting
  • End-stage Kidney Disease
  • SUPPORT-DIALYSIS with Access to Output Report and Information Hub
  • SUPPORT-DIALYSIS Only
  • Brampton, Ontario, Canada
  • +1 more
Aug 22, 2022

Gastric Cancer, Adjuvant Chemo, XO Trial in Seoul (Docetaxel and capecitabine and oxaliplatin, capecitabine and oxaliplatin)

Recruiting
  • Gastric Cancer, Adjuvant Chemotherapy, XO
  • Docetaxel and capecitabine and oxaliplatin
  • capecitabine and oxaliplatin
  • Seoul, Korea, Republic of
    Asan Medical Center
Dec 30, 2022

Anterior Cruciate Ligament Reconstruction Trial in Storrs (Active Comparator: 0.25 m/s asymmetric session first, Active

Recruiting
  • Anterior Cruciate Ligament Reconstruction
  • Active Comparator: 0.25 m/s asymmetric session first
  • Active Comparator: 0.50 m/s asymmetric session first
  • Storrs, Connecticut
    University of Connecticut
Jul 27, 2023

NSCLC, EGFR Sensitive Mutation, Adjuvant Therapy Trial in Beijing, Nanjing, Shanghai (Befotertinib + Icotinib , Icotinib +

Recruiting
  • Non-Small Cell Lung Cancer
  • +2 more
  • Befotertinib + Icotinib placebo
  • Icotinib + Befotertinib placebo
  • Beijing, China
  • +2 more
Sep 20, 2023

Esophageal Squamous Cell Carcinoma Trial in Fuzhou (adjuvant treatment)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • adjuvant treatment
  • Fuzhou, Fujian, China
    Fujian Medical University Union Hospital
Nov 10, 2021

Hematoma Postoperative Trial in Saskatoon (Ketorolac, Saline)

Recruiting
  • Hematoma Postoperative
  • Saskatoon, Saskatchewan, Canada
    St. Paul's Hospital
Apr 10, 2022